Pipeline

Discover our candidates

Our pipeline integrates the proprietary SnB light-activated payload with antibody- and peptide-based targeting strategies to address difficult-to-treat solid tumors through a novel dual-control approach. By combining molecular targeting with spatially controlled light activation, the platform is designed to enhance tumor selectivity while minimizing systemic exposure.

The proprietary DNA-based linker technology enables efficient conjugation to both commercially available and next-generation targeting molecules, supporting flexible program development across multiple oncology indications.